Immunocore (NASDAQ:IMCR) Sets New 52-Week Low – Here’s Why

Immunocore Holdings plc (NASDAQ:IMCR)’s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $27.19 and last traded at $27.74, with a volume of 124643 shares traded. The stock had previously closed at $29.00.

Analysts Set New Price Targets

A number of research firms have recently commented on IMCR. Needham & Company LLC reissued a “buy” rating and issued a $71.00 price target on shares of Immunocore in a research report on Wednesday. Morgan Stanley reissued an “equal weight” rating and set a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Wednesday. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $65.64.

Immunocore Trading Down 2.7 %

The business has a 50-day moving average price of $30.13 and a 200-day moving average price of $31.45. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $1.41 billion, a P/E ratio of -29.76 and a beta of 0.79.

Institutional Trading of Immunocore

Several institutional investors have recently made changes to their positions in IMCR. Principal Financial Group Inc. lifted its stake in Immunocore by 25.0% during the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after purchasing an additional 109,206 shares during the period. Assetmark Inc. raised its holdings in shares of Immunocore by 6.5% in the 3rd quarter. Assetmark Inc. now owns 30,555 shares of the company’s stock worth $951,000 after buying an additional 1,878 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in shares of Immunocore during the 3rd quarter worth approximately $866,000. GSA Capital Partners LLP acquired a new stake in Immunocore in the 3rd quarter valued at $406,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Immunocore by 7.5% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company’s stock valued at $13,297,000 after acquiring an additional 29,689 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.